Mayo Clinic radiotherapy outcomes registry and biobank
Official title: Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
Run by Mayo Clinic · NCT02457962 · Data updated 2026-11-12
This project collects blood and tissue from people with solid tumors or blood cancers treated with photon or proton radiotherapy at Mayo Clinic Rochester to see if biological markers link to side effects and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 15000 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | April 23, 2015 |
| Main results expected | April 30, 2031 |
| Study ends | April 30, 2031 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT02457962 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients with solid tumors or blood cancers receiving curative-intent photon or proton radiotherapy at Mayo Clinic Rochester are ideal candidates.
✕Probably not a fit
Patients treated with palliative radiation, those receiving care elsewhere, or patients who cannot provide samples or follow-up data are unlikely to benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry collects clinical data and biological specimens (for example blood and tissue) from patients with solid tumors or hematologic malignancies who receive photon or proton radiotherapy at Mayo Clinic in Rochester. Specimens and treatment details will be stored in a biobank and linked to clinical outcomes including acute and late toxicities, quality of life measures, local control, and survival. Patients treated with curative-intent radiation are eligible and no investigational interventions are given as part of participation. Researchers will use the linked samples and data to search for biomarkers or patterns that might predict side effects or treatment effectiveness.
Why it matters
Potential benefit: If successful, it could help doctors predict which patients are most likely to benefit from or be harmed by specific radiotherapy approaches and enable more personalized treatment plans.
How similar studies have gone: Other institutional radiotherapy biobanks and registries have produced promising biomarker leads linking biological signatures to toxicity and outcomes, but validation across centers remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Treated with photon/proton at Mayo Clinic Rochester in Radiation Oncology 2. Radiation therapy for curative intent Exclusion Criteria: None
Where it's running
-
Mayo Clinic
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Nadia N. Laack, MD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
INCA036873 for adults with advanced solid tumors and blood cancers.
This trial will test whether the experimental drug INCA036873 is safe and tolerable in adults with advanced or metastatic solid tumors or certain blood cancers who have already tried standard treatments.
-
Long-term evaluation of pembrolizumab for patients with advanced tumors
This study is testing how well pembrolizumab works and how safe it is for people with advanced tumors who have already been part of previous studies.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.